Dominant immune response to HLA-B57/B58 molecules after platelet transfusion

Area of Science:

• Immunology
• Transfusion Medicine
• Hematology

Background:

• Platelet transfusions are vital for patients with hematologic malignancies experiencing thrombocytopenia.
• Class I HLA antibodies can lead to immune-mediated platelet refractoriness, a significant complication.
• The mechanisms underlying alloimmunization in this context are not fully understood.

Purpose of the Study:

• To explore the immunogenicity of Human Leukocyte Antigen (HLA) molecules.
• To characterize the phenotype of HLA-specific CD4+ T cells involved in alloimmunization.
• To investigate the role of HLA molecules in platelet transfusion immunogenicity.

Main Methods:

• Retrospective cohort study involving men with specific anti-HLA antibodies who received transfusions.
• Investigation of the presence and phenotypic profile of HLA-specific CD4+ T cells in alloimmunized patients undergoing long-term platelet transfusion programs.
• Analysis of immune responses following specific HLA stimulation.

Main Results:

• Over 50% of transfused subjects showed an antibody response against HLA-B57 or HLA-B58.
• HLA-B57-specific CD4+ T-cell responses were detected in patients alloimmunized against HLA-B57.
• Stimulated patients exhibited HLA-specific CD4+ T cells producing TNF-α, IL-13, IL-17A, IL-2, IL-10, and IL-21.

Conclusions:

• The findings elucidate mechanisms of posttransfusion class I anti-HLA alloimmunization.
• This research represents a foundational step towards developing novel strategies to mitigate platelet refractoriness.
• Understanding T-cell responses to HLA is crucial for improving transfusion outcomes.